Table 2 Voriconazole
From: Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
Overall (n = 250) |  |  |  |
|---|---|---|---|
Drug concentration (μg/ml) (median [IQR]) |  | 2.43 (0.94–4.90) |  |
Comparison by drug level | Therapeutic drug level (n = 134) | Non-therapeutic drug level (n = 116) | p |
PK parameters | |||
 Drug concentration (μg/ml) (median [IQR]) | 2.6 (1.66–3.87) | 0.90 (0.45–7.97) | 0.10 |
 Total daily dose (mg) (median [IQR]) | 552 (400–800) | 600 (405–800) | 0.01 |
 mg/kg/dose (median [IQR]) | 3.95 (3.3–4.4) | 4.24 (3.7–5.5) | 0.01 |
 mg/kg/day (median [IQR]) | 7.76 (6.4–8.7) | 8.48 (7.5–11.0) | <0.01 |
 Weight (median [IQR]) | 70.8 (61.0–84.3) | 75.5 (58.6–88.75) | 0.65 |
  Subtherapeutic (n = 65) |  | 72 (56.5–94) | 0.90 |
  Supratherapeutic (n = 51) |  | 86.1 (76.1–102.7) | 0.36 |
 Concomitant interacting medications | 13 (10) | 15 (13) | 0.43 |
 Concomitant H2RA/PPI | 113 (85) | 92 (79) | 0.25 |
PK parameters—initial dose only | (n = 66) | (n = 57) |  |
 mg/kg/dose (median [IQR]) | 3.67 (2.9–4.2) | 4.03 (3.6–4.7) | 0.01 |
 mg/kg/day (median [IQR]) | 7.34 (5.8–8.4) | 8.07 (7.1–9.3) | 0.01 |
 Weight (median [IQR]) | 69.0 (60.5–82)a | 74.0 (58.1–85.5) | 0.69 |
  Subtherapeutic (n = 29) |  | 64.4 (49.5–79.3) | 0.11 |
  Supratherapeutic (n = 28) |  | 80.5 (68.1–88.8) | 0.054 |
Patient characteristics | |||
 Critically ill | 54 (40) | 47 (41) | 1.00 |
 Solid organ transplant recipients | 15 (11) | 17 (15) | 0.45 |
 Bone marrow transplant recipients | 41 (31) | 28 (24) | 0.26 |
 Cystic fibrosis | 17 (13) | 11 (9) | 0.55 |
 Immunocompromised | 90 (67) | 81 (70) | 0.68 |
Outcomes | |||
 Length of stay (days) (median [IQR]) | 31 (14–56) | 27 (8–41) | 0.12 |
 Adverse drug event requiring discontinuation | 1 (0.7) | 8 (7) | 0.01 |
 Treatment failure | 35 (26) | 44 (38) | 0.06 |
Comparison by patient | Therapeutic mean drug level (n = 74) | Non-therapeutic mean drug level (n = 48) |  |
|---|---|---|---|
Outcomes | |||
 Survive to hospital discharge (n = 122) | 56 (76) | 34 (71) | 0.67 |
 Treatment failure | 12 (16) | 21 (44) | <0.01 |
 Length of stay (days) (median [IQR]) | 22 (11–37) | 21 (7–37) | 0.25 |